Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

138.18 +0.54 (+0.39%)
Official Closing Price Updated: 7:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about AbbVie

< Previous 1 2 3 4 5 Next >
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer is a value and high-yield compared to its peers and it it outperforming expectations in 2023; The pipeline is robust. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
From Hagens Berman Sobol Shapiro LLP
Via Business Wire
AbbVie Inc. (NYSE: ABBV) Making Surprising Moves in Monday Session
Via Investor Brand Network
Why Next Week's Earnings Report is Good for Johnson & Johnson
Investors have had to digest some negative news headlines, but if you look past that a dividend king like JNJ can be a boring but reliable buy in this market 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
BioNTech Is Ripe For A Rebound In 2023
BioNTech had a strong quarter and may become a takeover target due to its healthy pipeline and a looming patent cliff for big pharma. 
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
These 3 Dividend Growers Yield More Than the 10-Year Note
Dividend aristocrats with yields greater than the 10-year note yield plus the potential for price appreciation could be a winning formula in this environment. 
Via MarketBeat
Topics Bonds
Exposures Debt Markets
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat
Diversify Your Income with These 2 High-Yielding Dividend ETFs
Diversification is a term widely used when it comes to investing in the stock market. It means spreading your investment across different sectors and indust 
Via MarketBeat
Topics ETFs
How to Pick the Best Dividend Stocks
A stock’s dividend yield is a key metric for investors, so what is a good dividend yield? We’ll explore the answer in this article. 
Via MarketBeat
Topics Economy
Exposures Interest Rates
The Stock That Tripled in a Day...And May Not Be Done
Reata Pharmaceuticals now has a long-coveted commercialized drug in its portfolio. Should investors covet this biotech stock for their portfolios? 
Via MarketBeat
Wall Street Sees 23% Upside In Revance, Maker Of Botox Competitor
Revance Therapeutics gapped up 54.34% on January 9, and built upon those gains in February. The company reported its first revenue for Botox competitor Daxxify. 
Via MarketBeat
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term. 
Via MarketBeat
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
MarketBeat Week in Review – 2/13 - 2/17
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
AbbVie Has a Mixed Outlook After Mixed Earnings
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold 
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
Is the Pain Over for Baudax Bio Investors after a 70% Spike?
Baudax Bio (NASDAQ: BXRX) shares spiked as much as 70% on its announcement of positive interim phase 2 clinical trials for its pain medicine BX1000. 
Via MarketBeat
AbbVie Stock: Dividend King ABBV Overview
Via MarketBeat
4 High-Yield Dividend Kings For 2023
These 3 Dividend Kings offer value and yield to investors and could outperform the group in 2023. That's good news for income investors. 
Via MarketBeat
AbbVie and Immunome Announce Strategic Collaboration to Discover Multiple Novel Oncology Targets
From Immunome, Inc.
Via Business Wire
Harpoon Therapeutics Remains Volatile After Promising News
Harpoon Therapeutics offers an example of biotech's volatility. The stock advanced as much as 191% intraday Monday before settling down to a gain of 22.61%. 
Via MarketBeat
Optimism Building for Advancing Pancreatic Cancer Treatment Therapies
EQNX::TICKER_START (NASDAQ:ONCY),(NYSE:RCUS),(NASDAQ:AZN),(NYSE:BMY),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
MarketBeat: Week in Review 11/14 – 11/18
This week, investors digested negative news from the retail sector and the Fed and next week's abbreviated trading week won't bring much new news. 
Via MarketBeat
Topics Economy Workforce
Exposures Economy Interest Rates Layoff
One in Five Americans Who Have Been Infected With the Virus Said to Have Long COVID
Palm Beach, FL – November 17, 2022 – FinancialNewsMedia.com News Commentary – Since the beginning of the pandemic, the critical effort of researchers is to understand how coronavirus damages the body.... 
Via FinancialNewsMedia
Exposures COVID-19
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
MarketBeat: Week in Review 10/31-11/4
You can count on MarketBeat to point you towards the stocks that are good opportunities. Here are some of the most popular articles from this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Why is AbbVie Stock Falling, but Still Good Long-Term?
Why is AbbVie stock dropping today but still a solid investment? Its solid base, robust pipeline and dividend support a long position in ABBV stock. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
As Sales of Botox and Juvederm Begin to Stall, the Abbvie Stock Price Drops
AbbVie Inc (NYSE:ABBV) AbbVie Inc (NYSE:ABBV) quarterly sales were below Wall Street’s expectations on Friday, primarily due to lower-than-anticipated income from its popular cosmetic filler Juvederm... 
Via PressReach
Topics Economy
Exposures Economy Interest Rates
Merck Nears Breakout Point After October Surprise Good News
Dow component Merck is within 2% of an all-time high after rallying 7.30% in the past month. It got a boost from news about two new treatments. 
Via MarketBeat
Topics Stocks
Exposures US Equities
Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
JNJ stock is seen as a defensive play which has typically done well in bear markets. But there is one issue that makes longer-term forecasts uncertain 
Via MarketBeat
Topics Economy
Exposures Economy
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.